ZyVersa Therapeutics, Inc.
ZVSA
$0.18
-$0.02-11.21%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -20.47% | 62.02% | 90.94% | 90.42% | 76.20% |
| Total Depreciation and Amortization | 92.68% | -158.65% | -133.65% | -108.65% | -184.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 45.79% | -93.81% | -99.12% | -98.94% | -83.03% |
| Change in Net Operating Assets | 446.47% | 924.93% | 25.02% | -63.08% | -107.40% |
| Cash from Operations | 34.83% | 45.48% | 30.14% | 13.66% | 6.69% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -40.09% | -63.97% | -82.22% | -65.72% | -39.64% |
| Repurchase of Common Stock | -- | -- | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | 100.00% |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 243.29% | 201.09% | 151.69% | 74.48% | 52.14% |
| Cash from Financing | -17.10% | -45.35% | -41.10% | -0.56% | 259.73% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 127.83% | 56.59% | -155.87% | 41.88% | 80.90% |